Chardan initiates Moonlake stock with buy rating on HS drug outlook
Chardan initiated coverage on Moonlake Immunotherapeutics (NASDAQ:MLTX) with a buy rating and $57 price target, citing potential in its HS drug. The stock trades at $10.80. The FDA has aligned on the efficacy package for sonelokimab, with approval anticipated in Q3 2027. Chardan assigns an 85% probability of approval. Cantor Fitzgerald reiterated an Overweight rating on MLTX.
How this was made
The 30-second read
Why it matters
Analyst initiation adds visibility; the $57 target implies >400% upside from current price.
Market read
New coverage and regulatory timeline create a short‑term catalyst for MLTX.
What to watch
Potential competition in hidradenitis suppurativa space and financing needs for commercial launch.
Background
Moonlake Immunotherapeutics is a micro‑cap biotech focusing on sonelokimab for hidradenitis suppurativa and psoriatic arthritis.
Ticker impact
Chardan initiates coverage on Moonlake Immunotherapeutics with a buy rating, $57 price target and notes FDA BLA acceptance timeline, providing fresh analyst insight.
upward pressure as investors price in the buy rating and approval probability.
New coverage with a high target and 85% approval probability creates a catalyst for buying.
Market effects
Positive signal for biotech firms developing dermatology biologics.
Limited to US-listed biotech investors.
Modest, confined to niche therapeutic area.
Counterpoint
Risk that BLA acceptance may be delayed or data may not meet expectations, limiting upside.
Key entities
- companyMoonlake Immunotherapeutics
Biotech developing sonelokimab.
- analystChardan
Initiated coverage with buy rating.
